imported>GreenC bot: Rescued 1 archive link; reformat 1 link. Wayback Medic 2.5

2022-05-11T03:00:20Z

Rescued 1 archive link; reformat 1 link. Wayback Medic 2.5

New page

{{Short description|Definct biotechnology company}}
{{Infobox company
| name = SemBioSys Genetics Inc.
| logo =
| type = [[Public company|Public]]
| genre =
| foundation =
| founder =
| location_city = [[Calgary, Alberta]]
| location_country = [[Canada]]
| location =
| locations =
| area_served =
| key_people = James Szarko, President and CEO
| industry = Biotechnology
| products =
| services =
| revenue =
| operating_income =
| net_income =
| assets =
| equity =
| owner =
| num_employees = Approximately 20
| parent =
| divisions =
| subsid =
| homepage = [http://www.sembiosys.com www.sembiosys.com]
| footnotes =
| intl =
}}
'''SemBioSys Genetics Inc.''' was a development stage [[agricultural]] [[biotechnology]] company. It utilized its patented [[safflower]] [[Pharming (genetics)|pharming]] platform to develop and make [[proteins]] and [[oils]] for the [[nutraceutical]], [[functional food]] and [[functional beverage|beverage]], and [[pharmaceutical]] industries. A [[University of Calgary]] spin-off (1994), SemBioSys became a publicly traded firm. Investors had included Bay City Capital, the [[Business Development Bank of Canada]], [[Dow AgroSciences]] (a Canadian subsidiary of The [[Dow Chemical Company]]), Royal Bank Ventures Inc. (now [[RBC Capital Partners]]), the [[University of Calgary]], Ventures West Capital Ltd., and Dr. [[Maurice Moloney]]. In May 2012, SemBioSys terminated its operations.<ref name=BankruptcyAnnouncement>[http://www.newswire.ca/en/story/975453/sembiosys-announces-first-quarter-results-and-provides-update-on-activities Press release May 15, 2012: SemBioSys Announces First Quarter Results and Provides Update on Activities] {{webarchive |url=https://web.archive.org/web/20120815152432/http://www.newswire.ca/en/story/975453/sembiosys-announces-first-quarter-results-and-provides-update-on-activities |date=August 15, 2012 }}</ref>

The company's strategy was to partner with other companies to enable the commercialization of products. Its lead pharmaceutical products under development were [[biosimilar insulin]] and [[ApoA-1 Milano|Apo AI(Milano)]]. In a phase I/II clinical trial, SemBioSys demonstrated that its safflower produced [[insulin]] (SBS-1000) is bioequivalent to [[humulin]], a commercially available insulin.<ref>The Pharma Letter. 30 March 2009. [http://www.thepharmaletter.com/file/87226/plant-derived-insulin-passes-first-human-study.html Plant-derived insulin passes first human study] {{webarchive |url=https://web.archive.org/web/20100627013319/http://www.thepharmaletter.com/file/87226/plant-derived-insulin-passes-first-human-study.html |date=June 27, 2010 }}</ref>

In 2007, SemBioSys formed a subsidiary, Botaneco Specialty Ingredients Inc., dedicated to the commercialization of SemBioSys’ products for cosmetic, [[personal care]] and prescription topical dermatology products. Botaneco produced, marketed, and sold its products under the brand name Hydresia. In October 2009, Botaneco merged with Quebec City-based Advitech, a health sciences and technology company.

In October 2011, SemBioSys signed a collaboration agreement with [[Tasly Pharmaceuticals]]<ref>[https://archive.today/20130118185547/http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=183562323 Bloomberg BusinessWeek Profile]</ref> of [[Tianjin]] (China) and its wholly owned subsidiary Tasly U.S.<ref>[Press Release | [https://web.archive.org/web/20160115041811/http://micro.newswire.ca/release.cgi?rkey=1910112827&view=36078-0&Start=&htm=0]]</ref> Tasly is of China's top five largest producers of [[traditional Chinese medicines]] (TCMs).<ref>[http://www.taslyint.com/show.aspx?id=394&cid=6 Tasly Export Statement] {{webarchive |url=https://web.archive.org/web/20150216042106/http://www.taslyint.com/show.aspx?id=394&cid=6 |date=February 16, 2015 }}</ref> Upon government approval, a new company called Tasly-SemBioSys Bio-Pharmaceuticals Co., Ltd. was incorporated in [[Tianjin]], China. The new company was structured as a Sino-Foreign Equity Joint Venture and seeks to develop and commercialize a variety of products including pharmaceutical, functional foods, and [[nutraceuticals]] for China and the world. However SemBioSys did not transfer any intellectual property to the joint venture<ref>[https://archive.today/20130203071947/http://www.stockhouse.com/bullboards/messagedetailthread.aspx?p=0&m=30901194&l=0&r=0&s=SBS&t=list SenBioSys News Release 2012-04-04 07:31 ET] Quote: "This partnership has not resulted in any financial benefit to SemBioSys to date and, as a result, the company has not transferred any intellectual property to the newly formed joint venture as of this date."{{deadlink|date=February 2015}}</ref> and Tasly terminated the agreement.<ref name=BankruptcyAnnouncement />

== See also ==
*[[Plant-made pharmaceuticals]]

==References==
{{Reflist|2}}

== External links ==
*[https://web.archive.org/web/20111005104805/http://www.sembiosys.com/ SemBioSys Website]
*[https://web.archive.org/web/20111014140433/http://www.tasly.com/en_web/index.aspx Tasly Website]

[[Category:Biotechnology companies of Canada]]

SemBioSys Genetics - Revision history

imported>GreenC bot: Rescued 1 archive link; reformat 1 link. Wayback Medic 2.5